文献速递胸部肿瘤头颈与中枢神经肿瘤

广泛期小细胞肺癌患者的预防性颅脑照射对比观察:一项多中心、随机、开放标签、3期试验

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-03-23

该研究在日本47家机构纳入224例对铂类双药化疗有应答且MRI确认无脑转移的广泛期小细胞肺癌患者,随机接受预防性颅脑照射(25 Gy/10次)或观察。最终分析中位总生存预防性颅脑照射组11.6个月 vs 观察组13.7个月(HR 1.27,95%CI 0.96-1.68;p=0.094),预防性颅脑照射未延长总生存。

要点

  • 预防性颅脑照射组中位总生存11.6个月,观察组13.7个月,HR 1.27(95%CI 0.96-1.68;p=0.094)。
  • 研究因无效 early termination,预防性颅脑照射未显示总生存获益。
  • 对化疗有应答且MRI确认无脑转移并定期随访MRI的患者,预防性颅脑照射非必需。

核心结论

  • 在该日本试验中,预防性颅脑照射对比观察未使广泛期小细胞肺癌患者获得更长的总生存。
  • 对初始化疗有应答且确认无脑转移、随访期间接受定期MRI检查的患者,预防性颅脑照射并非必需。

研究设计与样本

  • 在日本47家机构开展的随机、开放标签、3期研究。
  • 纳入对铂类双药化疗有应答且MRI无脑转移的广泛期小细胞肺癌患者224例,随机1:1分为预防性颅脑照射组113例和观察组111例。
  • 预防性颅脑照射方案为25 Gy,分10次,每次2.5 Gy。
  • 主要终点为总生存,在意向治疗人群中分析。

主要发现

  • 最终分析中位总生存预防性颅脑照射组11.6个月(95%CI 9.5-13.3)vs 观察组13.7个月(95%CI 10.2-16.4),HR 1.27(95%CI 0.96-1.68;p=0.094)。
  • 计划中期分析(2013年6月18日,前163例入组患者)中,预防性颅脑照射优于观察的贝叶斯预测概率为0.011%,研究因无效提前终止。
  • 3个月时最常见的3级或更差不良事件:厌食预防性颅脑照射组6例(6%,共106例)vs 观察组2例(2%,共111例);乏力3例(3%)vs 1例(<1%);下肢肌无力1例(<1%)vs 6例(5%)。
  • 两组均无治疗相关死亡。

临床怎么用

  • 原文结论指出,对初始化疗有应答且确认无脑转移、随访期间接受定期MRI检查的广泛期小细胞肺癌患者,预防性颅脑照射并非必需。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Results from a previous phase 3 study suggested that prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs overall survival compared with no prophylactic cranial irradiation in patients with extensive-disease small-cell lung cancer. However, because of the absence of brain imaging before enrolment and variations in chemotherapeutic regimens and irradiation doses, concerns have been raised about these findings. We did a phase 3 trial to reassess the efficacy of prophylactic cranial irradiation in the treatment of extensive-disease small-cell lung cancer. METHODS: We did this randomised, open-label, phase 3 study at 47 institutions in Japan. Patients with extensive-disease small-cell lung cancer who had any response to platinum-based doublet chemotherapy and no brain metastases on MRI were randomly assigned (1:1) to receive prophylactic cranial irradiation (25 Gy in ten daily fractions of 2·5 Gy) or observation. All patients were required to have brain MRI at 3-month intervals up to 12 months and at 18 and 24 months after enrolment. Randomisation was done by computer-generated allocation sequence, with age as a stratification factor and minimisation by institution, Eastern Cooperative Oncology Group performance status, and response to initial chemotherapy. The primary endpoint was overall survival, analysed in the intention-to-treat population. This trial is registered with the UMIN Clinical Trials Registry, number UMIN000001755, and is closed to new participants. FINDINGS: Between April 3, 2009, and July 17, 2013, 224 patients were enrolled and randomly assigned (113 to prophylactic cranial irradiation and 111 to observation). In the planned interim analysis on June 18, 2013, of the first 163 enrolled patients, Bayesian predictive probability of prophylactic cranial irradiation being superior to observation was 0·011%, resulting in early termination of the study because of futility. In the final analysis, median overall survival was 11·6 months (95% CI 9·5-13·3) in the prophylactic cranial irradiation group and 13·7 months (10·2-16·4) in the observation group (hazard ratio 1·27, 95% CI 0·96-1·68; p=0·094). The most frequent grade 3 or worse adverse events at 3 months were anorexia (six [6%] of 106 in the prophylactic cranial irradiation group vs two [2%] of 111 in the observation group), malaise (three [3%] vs one [<1%]), and muscle weakness in a lower limb (one [<1%] vs six [5%]). No treatment-related deaths occurred in either group. INTERPRETATION: In this Japanese trial, prophylactic cranial irradiation did not result in longer overall survival compared with observation in patients with extensive-disease small-cell lung cancer. Prophylactic cranial irradiation is therefore not essential for patients with extensive-disease small-cell lung cancer with any response to initial chemotherapy and a confirmed absence of brain metastases when patients receive periodic MRI examination during follow-up. FUNDING: The Ministry of Health, Labour and Welfare of Japan.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017. PMID: 28343976. doi:10.1016/S1470-2045(17)30230-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。